期刊
INTERNATIONAL IMMUNOPHARMACOLOGY
卷 74, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.intimp.2019.105677
关键词
Cryptotanshinone; STAT3; Systemic lupus erythematosus; T cell proliferation
资金
- National Natural Science Foundation of China [81700022, 81873102]
- National Key Research and Development Program of China [2018YFC1705501]
- National Industry Public Welfare Science and Technology Project [201507001-4]
- Research Fund of Zhejiang Chinese Medical University [111100E013/001/001/029, 111100E013/001/001/066]
Systemic lupus erythematosus (SLE) is a chronic, devastating autoimmune disorder associated with severe organ damage. Recently, the role of Signal Transducer and Activator of Transcription 3 (STAT3) in murine lupus has been described, suggesting the involvement of STAT3 signaling in the development of SLE. Cryptotanshinone (CTS) is an effective inhibitor of STAT3; however its potential as a SLE treatment remains to be explored. To determine the function of CTS in SLE, we treated MRL/lpr female mice with CTS. Firstly, we found CTS treatment reversed the elevated STAT3 signaling of spleens in lupus-prone MRL/lpr mice, accompanying with a dramatically decreased number of T cells, especially double-negative (DN) T cells. Further research showed that CTS inhibited T cell proliferation via suppressing of STAT3 activation in vitro and in vivo. Consistently, we also proved that CTS treatment significantly alleviated autoimmune response including notably diminished skin lesions, reduced spleen size and increased life span. In addition, CTS treatment decreased the levels of autoantibodies and pro-inflammatory cytokines, as well as normalized structure and function of kidneys. All these data suggested that CTS treatment depressed STAT3 phosphorylation, which resulted in blocked DN T cell proliferation and finally attenuated the spontaneous SLE development. Taken together, our data identify CTS as a potential therapeutic drug for SLE patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据